LifeZig System for Individuals with Alzheimer's Disease

描述(由申请者提供)：项目摘要：超过400万美国人患有阿尔茨海默病(AD)。焦虑、悲伤、抑郁、焦虑、孤立、不适、困惑和其他负面因素降低了AD患者的生活质量，给照顾者带来了沉重的负担。我们的项目目标是：(1)通过基于新颖的LifeZig系统的新的TOM-VC干预(治疗旧记忆-视频频道)提高AD患者及其家人/照顾者的生活质量；(2)开发简单易用的独立LifeZig系统，允许家人/照顾者创建/显示带有AD患者的旧照片、音乐和解说的个性化视频频道；作为对阿尔茨海默氏症的回忆疗法。我们创新的TOM-VC疗法使用AD患者的保留记忆簇和新的技术应用，创造一个具有愉快时刻的个性化环境。回忆治疗性多媒体通过电视上的个性化视频频道呈现给患者，基于重要的人生事件、家庭和其他宝贵的回忆，具有丰富的积极情绪。第一阶段证明了可行性：LifeZig被家庭/照顾者认为易于使用，他们报告说AD患者的幸福感得到了改善，焦虑症减少了。AD患者也表现出显著的愉悦和兴趣(生活质量提高的强烈指标)。在第二阶段，我们将最终确定LifeZig并进行一项随机纵向研究，以评估治疗效果(对照组：安慰剂视频频道和常规护理)。测量：[生活质量]：观察性情绪评定量表、老年受试者多维度观察量表、NPI；[认知与功能]：简易智力状态检查、日常生活活动能力、IADL；[负担]：NPI、照顾者负担量表、修订的记忆与行为问题量表。建议的商业应用：LifeZig产品将提供丰富的个性化治疗，以改善越来越多的AD患者的幸福感，并减轻照顾者负担，预计将通过推迟制度化和增加护理人员留住来降低护理成本。相关性：Lifezig系统和Tom-VC干预将为阿尔茨海默氏症提供新的活动和治疗工具，通过显著提高AD患者的生活质量和减轻照顾者的护理负担，为两个不断增长的人群(AD患者和照顾者)带来好处。

DESCRIPTION (provided by applicant): Project Summary: Over 4 million Americans suffer from Alzheimer's disease (AD). Agitation, sadness, depression, anxiety, isolation, discomfort, confusion, and other negative factors impose diminished quality of life for AD patients and significant burden for caregivers. Our project goals are: (1) to enhance the quality of life of AD patients and their families/caregivers with the new TOM-VC intervention (Therapeutic Old Memories-Video Channels) based on the novel LifeZig system; (2) to develop the easy-to-use self-contained LifeZig system, allowing family/caregivers to create/display personalized video channels with old photographs of AD patients, music, and narration; as a reminiscence therapy for Alzheimer's. Our innovative TOM-VC therapy uses preserved memory clusters from AD patients and novel technology application to create a personalized environment with pleasant moments. Reminiscence therapeutic multimedia is presented to patients via individualized video channels on television, rich in positive emotions, based upon important lifetime events, family, and other cherished memories. Phase I demonstrated the feasibility: LifeZig was considered easy-to-use by families/caregivers, who reported AD patients' improved well-being and reduced agitation. AD patients also showed a significant level of pleasure and interest (strong indicators of enhanced quality of life). In Phase II, we will finalize LifeZig and perform a randomized longitudinal study to assess the therapy effectiveness (control groups: placebo video channels and usual care). Measures: [quality of life]: Observed Emotion Rating Scale, Multidimensional Observation Scale for Elderly Subjects, and NPI; [cognitive and functional]: Mini-Mental State Exam, ADL, and IADL; and [burden]: NPI, Caregiver Burden Scale, and Revised Memory & Behavior Problems Checklist. PROPOSED COMMERCIAL APPLICATION: LifeZig products will provide a rich individualized therapy to improve the well-being of a growing number of AD patients, and decrease the caregiver burden, which is expected to lower the cost of care by delaying institutionalization and increasing nursing staff retention. Relevance: The Lifezig system and TOM-VC intervention will provide new activities and therapy tools for Alzheimer's, bringing benefits to two growing populations (AD patients and caregivers), by significantly enhancing AD patient's quality of life, and decreasing caregiver's burden of care.